<?xml version="1.0" encoding="UTF-8"?>
<p>This study enrolled adults (&gt;18 years) with RA who fulfilled the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism classification criteria 
 <xref rid="sct312331-bib-0020" ref-type="ref">20</xref> and had a baseline 28‚Äêjoint count disease activity score (DAS28; using the erythrocyte sedimentation rate [ESR]) &gt; 3.2. The requirement for all patients was to be on a stable dose of methotrexate (MTX), for at least 12 weeks. The exclusion criteria were as follows: a history of or current rheumatic diseases or an autoimmune joint disease other than RA, a functional class IV status as defined by the ACR Classification of Functional Status in RA 
 <xref rid="sct312331-bib-0021" ref-type="ref">21</xref>, pregnancy or breastfeeding, a prior malignancy, or an active infection. Patients with a history of incompletely treated tuberculosis, or a conspicuous infection within 4 weeks before screening were also excluded.
</p>
